ropeginterferon alfa-2b + ribavirin

Ropeginterferon alfa-2b (P1101) is a long-lasting, mono-pegylated type I interferon engineered for improved purity and extended activity. It acts by binding to the interferon alpha/beta receptor complex, activating the JAK/STAT signaling pathway, which leads to antiviral, antiproliferative, anticancer, and immune-modulating effects. Ropeginterferon alfa-2b is approved for polycythemia vera and under investigation for essential thrombocythemia. Ribavirin is a nucleoside analog with broad-spectrum antiviral activity; it inhibits viral RNA synthesis and replication. The combination of ropeginterferon alfa-2b with ribavirin has been explored in clinical settings—especially in viral hepatitis—leveraging their complementary mechanisms: immunomodulation by interferons and direct inhibition of viral replication by ribavirin[1][3][6][8].

Brand names

Besremi (for ropeginterferon alfa-2b)

Other names

Ropeginterferon alpha 2b-njftmono-pegylated interferon alpha 2b (for P1101)ribavirin